These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 8149546

  • 1. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ.
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [Abstract] [Full Text] [Related]

  • 2. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 3. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ, Prager NA, Sobel BE, Abendschein DR.
    Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
    [Abstract] [Full Text] [Related]

  • 4. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.
    Nicolini FA, Lee P, Malycky JL, Lefkovits J, Kottke-Marchant K, Plow EF, Topol EJ.
    Blood Coagul Fibrinolysis; 1996 Jan; 7(1):39-48. PubMed ID: 8845461
    [Abstract] [Full Text] [Related]

  • 5. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS, Zoldhelyi P, Webster MW, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH.
    Circulation; 1996 Feb 15; 93(4):792-9. PubMed ID: 8641009
    [Abstract] [Full Text] [Related]

  • 6. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun 15; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP.
    Circulation; 1992 Feb 15; 85(2):805-15. PubMed ID: 1735171
    [Abstract] [Full Text] [Related]

  • 9. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ, Sitko GR, Mellott MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddie CT, Vlasuk GP.
    Cardiovasc Res; 1994 Jan 15; 28(1):78-85. PubMed ID: 8111795
    [Abstract] [Full Text] [Related]

  • 10. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U, Dörge L, Fischer S.
    Br J Pharmacol; 1996 May 15; 118(2):271-6. PubMed ID: 8735626
    [Abstract] [Full Text] [Related]

  • 11. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR, Lynch JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD.
    J Pharmacol Exp Ther; 1993 Sep 15; 266(3):1501-11. PubMed ID: 8371153
    [Abstract] [Full Text] [Related]

  • 12. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec 15; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec 15; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 15. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb 15; 23(2):203-11. PubMed ID: 7511748
    [Abstract] [Full Text] [Related]

  • 16. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr 15; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 17. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.
    Prager NA, Torr-Brown SR, Sobel BE, Abendschein DR.
    J Am Coll Cardiol; 1993 Jul 15; 22(1):296-301. PubMed ID: 8509554
    [Abstract] [Full Text] [Related]

  • 18. Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis.
    Martin U, Sponer G, Strein K.
    Int J Hematol; 1992 Oct 15; 56(2):143-53. PubMed ID: 1421176
    [Abstract] [Full Text] [Related]

  • 19. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
    Nichols WW, Nicolini FA, Khan S, Saldeen TG, Mehta JL.
    Am Heart J; 1993 Aug 15; 126(2):285-92. PubMed ID: 7687816
    [Abstract] [Full Text] [Related]

  • 20. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS, Bentley RG, Morgan SR, Kasiewski CJ, Chu V, Perrone MH, Leadley RJ.
    Br J Pharmacol; 2001 Aug 15; 133(7):1190-8. PubMed ID: 11487531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.